Podcasts about inventiv health

Recorded on 06/30/23 Over the last decade, contract research organizations (CROs) have become an increasingly important stakeholder in the clinical trial process. Over half of biopharma R&D budgets are outsourced to CROs, up from less than one-third ten years ago. With the high costs of drug development and importance of time to approval, CROs are relied upon for trial expertise, site networks, and abilities to accelerate KPIs such as study start up and recruitment timelines. Following a period of heightened biopharma funding during the pandemic that fueled demand for CRO services, we now enter a period of uncertainty as to where R&D budgets go from here and whether CROs can innovate their people-intensive processes to improve drug development costs and timelines going forward. To discuss these topics, we are joined by Rene Stephens. Rene leads Renatus Consulting, an independent advisory to CRO and life science clients. His experience spans the outsourced clinical trial procurement process, including procurement and contract negotiation during his time at Pfizer and Astellas, as well as business development during his time at inVentiv Health. For Disclosures, click here bit.ly/3cPHkNW

Welcome friends, to our new podcast, The Patients Speak, where we combine the business and science innovations in healthcare with the patient voice, the patient experience, and activating patients to be more involved and more empowered in their own healthcare. Today's guest is Shefali Shah, she's global VP of market access and commercial effectiveness for a company called MindMaze, a brain technology and neurorecovery company. She is an expert in evidence-based strategies for digital healthcare. Her background includes market access for pharmas, including GSK, Novo Nordisk, and InVentiv Health (now Syneos)Shefali defines digital therapeutics as evidence-based therapeutic or an intervention that uses software to manage or prevent a disease. She emphasizes that MindMaze combines different modalities to create an immersive experience for the patient. So it is not just about the software, it is also about integrating the therapist, the care team, and the hardware.Shefali explains that as much as the games are a basis of their platform it does require a lot more than a game. They understand that patients are going to learn differently and are going to need a lot of different modalities to overcome some of the challengesWe discussed how MindMaze built a system incorporating the patient's voice and she gave a few examples of how they do it.Many members of the product team themselves have survived a stroke or other traumatic brain injuriesBeyond the team, they engage patient advisors to help in developing the productBringing therapists into the product-design processPatient research by listening to unfiltered recovery stories on social platforms She acknowledged that the treatments, therapies, and medicines patients need across each of these stages are very different. So they take very real-world experiences and then connect the inpatient and outpatient and home-care settings -- all of those in designing the trials.We dove deep into those unforeseen challenges in the patient journey for example:When a patient almost lost their houseOr their caregivers left them because they could not afford a nurse to come inThey were just tired of taking care of the patient themselvesOr their insurance just stopped covering because they went from one set of care to another.We also spoke about the challenges she is facing in bringing these products to the market.There are market access challenges around the different reimbursement pathways that have been designed for the different sites of care.In summary, she says part of the solution is to create Therapy Integration Managers that take the patient from one site of care to another. They would be considered as a medical concierge to help patients transition through different sets. In conclusion, we talk about collaboration with different organizations to bring this category of digital therapeutics to life. The APTA and the AAN clinical societies, and also patient advocacy groups, would go a long way to help focus on the entire patient journey.Shefali Shah Shefali BSB Media

Carlo Gualandri fondatore di Soldo, la piattaforma leader per l'automazione della gestione dei costi e dei pagamenti che ottimizza trasferte, acquisti, pubblicità online, servizi software e di tutte le altre tipologie di costi aziendali. Soldo fornisce una visione completa ed integrata della spesa per l'intera organizzazione, dalla decisione su come allocare i fondi all'esecuzione dei pagamenti e alla loro contabilizzazione. Carlo Gualandri è il fondatore di Soldo per le aziende in Europa. In precedenza, ha fondato Gioco Digitale, Virgilio, il primo portale italiano e il network di pubblicità online Active Advertising. Ha gestito inoltre lo sviluppo delle Pagine Gialle Online, ha guidato la divisione Internet di Telecom Italia e partecipato alla startup di Fineco, la banca online leader in Italia. Siti, app e link utili Soldo Digitalmagics Marco Gay presidente esecutivo di Digital magics. Torinese, nato nel 1976, Marco Gay, è sposato e ha tre figli. La famiglia rappresenta uno dei valori essenziali della sua vita e trova in essa larga parte delle sue motivazioni. Le sue radici provengono da una famiglia imprenditoriale e industriale, che all'insegna dei valori e dell'etica ha formato il suo carattere e la sua visione della vita, che si è arricchita e rafforzata con le esperienze che ha avuto la fortuna di vivere. Crescere a contatto con l'azienda e con la gestione aziendale è stato uno dei master più proficui che abbia potuto seguire. Dal 2000 è Co-Founder e CEO di WebWorking, occupandosi di Management aziendale con specializzazione in Management for business, in particolare Business Strategy, Communication, Web Marketing. Nel 2007 acquisisce quote della società Ottovolante, società specializzata in Digital Project per il settore farmaceutico e ne diventa l'Amministratore Delegato. Successivamente entra nell'agenzia pubblicitaria GSW WorldWide Italy come CEO, con il compito di integrare l'agenzia con il network internazionale inVentiv Health. Il 30 novembre 2015 diventa socio di Digital Magics, incubatore di startup quotato su Mercato Euronext Growth Milan e da novembre 2015 a dicembre 2017 è stato Vicepresidente Esecutivo di Digital Magics. Nel dicembre 2017 Marco Gay è stato nominato Amministratore Delegato di Digital Magics e nel dicembre 2022 ne diventa Presidente Esecutivo. Digital Magics, quotata su AIM Italia (simbolo: DM), è un business incubator di progetti digitali che fornisce servizi di consulenza e accelerazione a startup e imprese, per facilitare lo sviluppo di nuovi business tecnologici. Digital Magics, Talent Garden e Tamburi Investment Partners hanno creato il più importante hub nazionale di innovazione per il DIGITAL MADE IN ITALY, offrendo alle startup innovative il supporto per creare progetti di successo, dall'ideazione fino all'IPO. Digital Magics è da sempre partner delle imprese eccellenti con i propri servizi di Open Innovation, creando un ponte sinergico fra le aziende e le startup digitali. I servizi di incubazione e di accelerazione di Digital Magics sono attivi nei campus di coworking Talent Garden presenti in tutta Italia. Complementari ai servizi sono le attività di investimento, che hanno prodotto negli anni un portafoglio di oltre 70 partecipazioni in startup, scaleup e spinoff digitali con alti tassi di crescita.

Carlo Gualandri fondatore di Soldo, la piattaforma leader per l'automazione della gestione dei costi e dei pagamenti che ottimizza trasferte, acquisti, pubblicità online, servizi software e di tutte le altre tipologie di costi aziendali. Soldo fornisce una visione completa ed integrata della spesa per l'intera organizzazione, dalla decisione su come allocare i fondi all'esecuzione dei pagamenti e alla loro contabilizzazione. Carlo Gualandri è il fondatore di Soldo per le aziende in Europa. In precedenza, ha fondato Gioco Digitale, Virgilio, il primo portale italiano e il network di pubblicità online Active Advertising. Ha gestito inoltre lo sviluppo delle Pagine Gialle Online, ha guidato la divisione Internet di Telecom Italia e partecipato alla startup di Fineco, la banca online leader in Italia. Siti, app e link utili Soldo DigitalmagicsMarco Gay presidente esecutivo di Digital magics. Torinese, nato nel 1976, Marco Gay, è sposato e ha tre figli. La famiglia rappresenta uno dei valori essenziali della sua vita e trova in essa larga parte delle sue motivazioni. Le sue radici provengono da una famiglia imprenditoriale e industriale, che all'insegna dei valori e dell'etica ha formato il suo carattere e la sua visione della vita, che si è arricchita e rafforzata con le esperienze che ha avuto la fortuna di vivere. Crescere a contatto con l'azienda e con la gestione aziendale è stato uno dei master più proficui che abbia potuto seguire. Dal 2000 è Co-Founder e CEO di WebWorking, occupandosi di Management aziendale con specializzazione in Management for business, in particolare Business Strategy, Communication, Web Marketing. Nel 2007 acquisisce quote della società Ottovolante, società specializzata in Digital Project per il settore farmaceutico e ne diventa l'Amministratore Delegato. Successivamente entra nell'agenzia pubblicitaria GSW WorldWide Italy come CEO, con il compito di integrare l'agenzia con il network internazionale inVentiv Health. Il 30 novembre 2015 diventa socio di Digital Magics, incubatore di startup quotato su Mercato Euronext Growth Milan e da novembre 2015 a dicembre 2017 è stato Vicepresidente Esecutivo di Digital Magics. Nel dicembre 2017 Marco Gay è stato nominato Amministratore Delegato di Digital Magics e nel dicembre 2022 ne diventa Presidente Esecutivo. Digital Magics, quotata su AIM Italia (simbolo: DM), è un business incubator di progetti digitali che fornisce servizi di consulenza e accelerazione a startup e imprese, per facilitare lo sviluppo di nuovi business tecnologici. Digital Magics, Talent Garden e Tamburi Investment Partners hanno creato il più importante hub nazionale di innovazione per il DIGITAL MADE IN ITALY, offrendo alle startup innovative il supporto per creare progetti di successo, dall'ideazione fino all'IPO. Digital Magics è da sempre partner delle imprese eccellenti con i propri servizi di Open Innovation, creando un ponte sinergico fra le aziende e le startup digitali. I servizi di incubazione e di accelerazione di Digital Magics sono attivi nei campus di coworking Talent Garden presenti in tutta Italia. Complementari ai servizi sono le attività di investimento, che hanno prodotto negli anni un portafoglio di oltre 70 partecipazioni in startup, scaleup e spinoff digitali con alti tassi di crescita.

The Future of Pharmacy: The future of pharmacy is being disrupted & we see the creation of transformative opportunities but with great challenges. How will the future of pharmacy take shape? As innovations in life sciences and new technology disrupt the health care value chain, consumers are increasingly focused on well-being, demanding greater health care access, convenience, and customized products. In this environment, exciting opportunities emerge for pharmacists to evolve and expand their role. https://www2.deloitte.com/us/en/pages/life-sciences-and-health-care/articles/future-of-pharmacy-disruption-opportunities-challenges.html George Van Antwerp Senior Manager, Deloitte Consulting LLP  https://www.linkedin.com/in/vanantwerp/ George Van Antwerp is a leader in Deloitte Consulting's Health Plan and Pharmacy practice where he works with clients on insights and analysis to improve their competitive positioning. Prior to joining Deloitte, George worked with inVentiv Health in their Medical Management business, and he led the pharmacy business for Silverlink Communications.  George also worked at Express Scripts where he focused on their consumer engagement solutions.  George holds an MBA and MA from Washington University in St. Louis and received his BS from the University of Michigan in Ann Arbor. Discussion references: Community-Based Pharmacy Practice Innovation and the Role of the Community-Based Pharmacist Practitioner in the United States https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789634/ Medical at Home: A Game-changing Opportunity for Long-Term Care With 10,000 Americans aging into Medicare daily, some pharmacies have grown their market share by offering medical-at-home services to keep patients who might otherwise be in a nursing home in the familiarity of their homes longer. https://ncpa.org/newsroom/qam/2021/06/08/qam-ed-medical-home-game-changing-opportunity-long-term-care Thank you RxSafe for sponsoring this episode! See omnystudio.com/listener for privacy information. Learn more about your ad choices. Visit megaphone.fm/adchoices

The Future of Pharmacy: The future of pharmacy is being disrupted & we see the creation of transformative opportunities but with great challenges. How will the future of pharmacy take shape? As innovations in life sciences and new technology disrupt the health care value chain, consumers are increasingly focused on well-being, demanding greater health care access, convenience, and customized products. In this environment, exciting opportunities emerge for pharmacists to evolve and expand their role. https://www2.deloitte.com/us/en/pages/life-sciences-and-health-care/articles/future-of-pharmacy-disruption-opportunities-challenges.html George Van Antwerp Senior Manager, Deloitte Consulting LLP  https://www.linkedin.com/in/vanantwerp/ George Van Antwerp is a leader in Deloitte Consulting's Health Plan and Pharmacy practice where he works with clients on insights and analysis to improve their competitive positioning. Prior to joining Deloitte, George worked with inVentiv Health in their Medical Management business, and he led the pharmacy business for Silverlink Communications.  George also worked at Express Scripts where he focused on their consumer engagement solutions.  George holds an MBA and MA from Washington University in St. Louis and received his BS from the University of Michigan in Ann Arbor. Discussion references: Community-Based Pharmacy Practice Innovation and the Role of the Community-Based Pharmacist Practitioner in the United States https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789634/ Medical at Home: A Game-changing Opportunity for Long-Term Care With 10,000 Americans aging into Medicare daily, some pharmacies have grown their market share by offering medical-at-home services to keep patients who might otherwise be in a nursing home in the familiarity of their homes longer. https://ncpa.org/newsroom/qam/2021/06/08/qam-ed-medical-home-game-changing-opportunity-long-term-care Thank you RxSafe for sponsoring this episode! See omnystudio.com/listener for privacy information.

Topic Discussed : Mergers and acquisiton landscape in the Lifescience Industry Speaker : Khushbu JainKey Takeaways: Pharma companies are seeking radical and immediate growth through M&A. Conversely, we can expect a lower volume of total deals but a higher average deal value Diagnostic and research tools segments on the other hand can extract value from inorganic growth by thinking beyond data curation and more about deriving & utilizing insightsOn that note, I hope you enjoyed this session.Please join us for future podcasts and become a member of our Leadership CouncilEmail us at digital@frost.com. Thank you for your time.Related Keywords: Mergers and Acquisitions in Life Science, mega-mergers, mega-acquisitions, M&A in pharma, M&A in biopharma, M&A in contract research organizations, M&A in contract development and manufacturing organizations, M&A in diagnostics, cell and gene therapy, patient engagement 2.0, patient centricity, connected health, Medication Adherence, Remote Monitoring, Tele Health, Direct to Consumer Genetic Testing, Companion Diagnostic & Biomarker Discovery, Liquid Biopsy, Cell and Gene Therapy, Pharmacogenomics, Artificial Intelligence, Big Data, RWE, Blockchain, IIoT, Outsourcing, X-as-a-Service, Data Monetization, Private equity investment, FAMGA, non-traditional healthcare players, fortune 50, Charles River, Eurofins Scientific, ICON Plc, IQVIA, LabCorp, Parexel, PPD, PRA Health, Syneos Health (INC Research and inVentiv Health), Wuxi Apptech, AMRI, Patheon, Cambrex, Catalent, Lonza, Piramal, Recipharm, Samsung Biologics, Siegfried, BioXcellence , Bio-Rad, Thermo Fisher, Perkin Elmer, Agilent Technologies, Qiagen, Danaher, Sysmex, Roche Diagnostics, Illumina, Becton Dickinson, bioMerieux, Pfizer, Roche, AstraZeneca, GSK, Novartis, Merck, Sanofi, AbbVie, Bristol-Myers Squibb, Jefferies Financial Group, Montagu Private Equity, Nordic Capital, Capstone, Catapult Partners Website: www.frost.com See acast.com/privacy for privacy and opt-out information.

In this episode of Glassdoor Reviews, we review the now number two CRO in the clinical research space Syneos Health which was a merger between Inc Research and Inventiv Health. These two CRO's became one in the merger and the merger has taken place just last year. The origin of Syneos has recently just celebrated their one year old anniversary. I hope you enjoy this breakdown of the number 2 CRO in the space. Don't forget to Subscribe for new content! Subscribe: https://youtube.com/eliteclinicalrese... Call or Text: 910-502-3732 Email: eliteclinicalgroup@gmail.com Podcast: https://anchor.fm/clinical-research-p... Steemit: https://steemit.com/@ecrgmedia Advertise: eliteclinicalgroup@gmail.com Watch: » Industry News: https://goo.gl/fNXpQ5 » All Videos: https://goo.gl/87XEFW » Interview Recaps: https://goo.gl/wJsk6W » Glassdoor Reviews: https://goo.gl/AbQzqe We do: » Insider Interviews » Resume Reviews » Question and Answer » Discuss all things Clinical Research » News and Product Reviews » Education --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/clinical-research-podcast/message Support this podcast: https://anchor.fm/clinical-research-podcast/support

Many people are interested in getting a job at one of the top CRO's, be it Syneos Health (Inc research + inVentiv Health), Parexel, IQVIA (Quintiles) or PPD or at the site or sponsor level, this video will detail what is needed to get your foot in the door in clinical research. Clinical research has become an increasingly competitive space to get your foot in the door and requires experience, networking and hustle. Even though there is a tremendous shortage of talent in the Clinical Research space, they are looking for people with experience usually and will take some hustle and flexibility in order to get to where exactly you want. Hope this helps. Subscribe on youtube: https://www.youtube.com/channel/UCe_8NUyFNS-dBLWq5Mi0eJg --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/clinical-research-podcast/message Support this podcast: https://anchor.fm/clinical-research-podcast/support

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: Novartis, Antares Vision, Syneos Health, Celgene, Impact Biomedicines, Pfizer, Roche, Techdow Pharma, Spark Therapeutics, Chiltern.Persone: Elisabeth Barrett (Novartis), Robert Kowalski (Novartis), Robert Landewé (Amsterdam Rheumatology Center).Nuove terapie: secukinumab, adalimumab, antidemetilasi & antideacetilasi, palbociclib, ocrelizumab, Inhixa, Luxturna.Patologie: Alzheimer, Parkinson, spondilite anchilosante, artrite psoriasica, cancro, tumore al seno, sclerosi multipla, trombosi, retinopatia ereditaria.Lavoro: CRA, Regulatory Affairs.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: Novartis, Antares Vision, Syneos Health, Celgene, Impact Biomedicines, Pfizer, Roche, Techdow Pharma, Spark Therapeutics, Chiltern.Persone: Elisabeth Barrett (Novartis), Robert Kowalski (Novartis), Robert Landewé (Amsterdam Rheumatology Center).Nuove terapie: secukinumab, adalimumab, antidemetilasi & antideacetilasi, palbociclib, ocrelizumab, Inhixa, Luxturna.Patologie: Alzheimer, Parkinson, spondilite anchilosante, artrite psoriasica, cancro, tumore al seno, sclerosi multipla, trombosi, retinopatia ereditaria.Lavoro: CRA, Regulatory Affairs.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple

What's in a name? Quite a lot, actually, despite what Shakespeare says. When it comes to a merger, this can be even more important.  With research showing that up to 80% of mergers fail – and one major reason being clashing corporate cultures during post-merger integration – choosing a name and brand that the entire organization can get behind is critical to success. In this episode, listen to Kristen Spensieri of Syneos Health and Joe Daley of Syneos Health branding firm Addison Whitney discuss how the company is walking the talk – rebranding its own organization after the 2017 merger of INC Research and inVentiv Health, and how these principles can be applied to any company going through a rebrand. Listen to Part 2 of our Naming series here. See our full list of podcast episodes here.   The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter. The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. Syneos Health reserves the right to make alterations or deletions to the content at any time without notice to you. Syneos Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content. The information, data and other content contained in this podcast is not a reflection of, endorsed by or otherwise affiliated with, nor should it be attributed to, any Syneos Health clients, customers or other contacts.

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: AstraZeneca, Aspen, Genenta Science, QuintilesIMS, LabCorp, Covance, PPD, Icon, INC Research, inVentiv Health, PRA Health Sciences, Parexel, BioClinica, Medpace, Premier Research, Teva Pharmaceuticals, Lundbeck, FDA, Amgen, Persone: Pierluigi Paracchi (Genenta Science), Luigi Naldini (Genenta Science) e Bernhard Gentner (Genenta Science), Guido Guidi (Genenta Science), Kenneth C. (Genenta Science), Kare Schultz (Teva Pharmaceuticals), Vytenis Andriukaitis (European Commissioner for Health and Food Safety), Jean-Pierre Bourguignon (European Research Council), Andrea Fontanella (FADOI).Nuove terapie: Mvasi, olaratumab.Patologie: sepsi, Parkinson, cancro, sarcoma.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: AstraZeneca, Aspen, Genenta Science, QuintilesIMS, LabCorp, Covance, PPD, Icon, INC Research, inVentiv Health, PRA Health Sciences, Parexel, BioClinica, Medpace, Premier Research, Teva Pharmaceuticals, Lundbeck, FDA, Amgen, Persone: Pierluigi Paracchi (Genenta Science), Luigi Naldini (Genenta Science) e Bernhard Gentner (Genenta Science), Guido Guidi (Genenta Science), Kenneth C. (Genenta Science), Kare Schultz (Teva Pharmaceuticals), Vytenis Andriukaitis (European Commissioner for Health and Food Safety), Jean-Pierre Bourguignon (European Research Council), Andrea Fontanella (FADOI).Nuove terapie: Mvasi, olaratumab.Patologie: sepsi, Parkinson, cancro, sarcoma.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple

Channels of influence in pharma have expanded from the traditional offline sphere of publications, trials, conference activities and others to include a vast new digital landscape that is shaping the way we need to interact with a new generation of key opinion leaders -- so-called "digital" KOLs. Digital KOLs have an "omnipresent" digital footprint that can include social media, independent websites, healthcare professional discussion platforms like SERMO and Doximity and a seemingly endless number of other potential channels. So what does this mean for those trying to find and reach out to these key influencers? Nick Lapolla, Manager, KOL Market Research at inVentiv Health Research and Insights and Madeline Rounds, Consultant on the inVentiv Health Medical Communications team, discuss how KOL mapping in this new age is both easier and harder than it used to be, highlight best practices and tactics and explain why it's still necessary to keep a human element in the mix. The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter. The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. inVentiv Health reserves the right to make alterations or deletions to the content at any time without notice to you. inVentiv Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content. The information, data and other content contained in this podcast is not a reflection of, endorsed by or otherwise affiliated with, nor should it be attributed to, any of inVentiv Health's clients, customers or other contacts.

The patient standing at the pharmacy to fill a prescription represents the "final mile" that started in the laboratory. All the science and commercial investment comes down to this one decision point. Will the patient walk away? What will get them to stay? In a survey of 200,000 retail prescriptions for the top 100 branded oral drugs, two inVentiv companies - Adheris Health and inVentiv Health Consulting - set out to understand the most influential factors to driving patient adherence or non-adherence. Jeff Stewart sits down with Linda Morini, Senior Director, Analytic Services and Mike Occhipinti, Vice President, Analytics at Adheris Health, to discuss what they found. Interested in learning more about the complex issue of adherence? Check out the inVentiv Health Communications white paper on social centricity, which discusses social forces that shape patient decisions. The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter. The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. inVentiv Health reserves the right to make alterations or deletions to the content at any time without notice to you. inVentiv Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content. The information, data, and other content contained in this podcast is not a reflection of, endorsed by or otherwise affiliated with, nor should it be attributed to, any of inVentiv Health's clients, customers or other contacts.

At the inaugural Patients as Partners Europe event, Duncan Arbour from inVentiv Health explores the ‘how’ and ‘when’ for involving patients within clinical and commercial to enhance the development and delivery of innovative therapies.  The patient voice as a strategic driver is being included much earlier in the development process than ever before. In this session, pharmaceutical, biotech and device companies will gain insight into the value of smarter patient integration. Key focus areas include: • The critical shift from drug-centric to patient-relevant • Pivotal patient touch points throughout clinical development and launch planning that will maximize both clinical and commercial outcomes • Positive impact of integration on efficiency and commercialization The Patients as Partners Europe program seeks to understand and incorporate the patient's voice in designing clinical trials and developing a clinical endpoint, as well as vastly improve the patient's entire experience in a clinical trial. The 2nd annual Patients as Partners EU event will be held January 23-24, 2018 at Radisson Blu Portman Hotel, London, UK.

At the BIO International Convention, arguably the largest and most important biopharma partnering event of the year with over 16,000 participants, it's all about getting the deal done. While the industry will very likely not see the extremely high level of licensing and M&A activity it did back in 2015, the year is shaping up to reach a respectable level closer to historical norms, according to Sachin Purwar, Senior Engagement Manager in the Commercial Strategy & Planning practice of inVentiv Health Consulting and one of the authors of the 2017 Dealmakers' Intentions Study -- the ninth in a series and a forward-looking measure of dealmaking activity in the pharmaceutical and biotech industries. What are buyers interested in this year, and what do sellers have to offer? Where is there a buyers' market, and where a sellers' market? What are the hot therapeutic areas and technologies to watch? What is the discount rate spread, and what does that mean for getting deals done? Why is the deal success rate so low -- and why is this good news? Host Jeff Stewart sits down with Sachin to answer these questions -- and discuss the year ahead for dealmaking in the biopharma industry.   The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements, or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter. The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. inVentiv Health reserves the right to make alterations or deletions to the content at any time without notice to you. inVentiv Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content. The information, data, and other content contained in this podcast is not a reflection of, endorsed by or otherwise affiliated with, nor should it be attributed to, any of inVentiv Health's clients, customers or other contacts.

Originally recorded during the 3rd annual Immuno-Oncology 360° in February 2017, this panel discussion addresses clinical challenges within immuno-oncology. One of the IO360° lead advisors, Dr James Gulley of the National Cancer Institute, moderates the session between Merck’s Dr Roy Baynes, nanoString Technologies’ Dr Alessandra Cesano, MD Anderson’s Dr Patrick Hwu, and inVentiv Health’s Robert Millham. Dr Hwu and Dr Baynes are also speaking on the 2nd annual Rational Combinations 360° program in June 2017, which is an exciting meeting dedicated to combination therapy in IO. Save the date for the 4th annual IO360° conference, taking place February 7-9, 2018 in New York City.  

According to Leigh Householder, Managing Director of Innovation for inVentiv Health Communications, in an industry where the appetite for innovation and change is strong, but the tolerance for risk is not, the answer lies in an accountable, data-driven marketing approach that allows for "targeted innovation” and leads to measurable impact. inVentiv Health Podcast host Jeff Stewart talks with Leigh about the value of predictive analytics in endlessly experimenting with channels and messages without spending a single dollar on in-market pilots. They'll also discuss why the 70/20/10 approach to planning is important -- including how it worked for the BBC -- and the potential impact of the millennial physician on pharma's marketing decisions. Have a listen to hear the latest in truly innovative customer and physician engagement tools and technologies that hint at the future of pharma communications. The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements, or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter. The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. inVentiv Health reserves the right to make alterations or deletions to the content at any time without notice to you. inVentiv Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content. The information, data, and other content contained in this podcast is not a reflection of, endorsed by or otherwise affiliated with, nor should it be attributed to, any of inVentiv Health's clients, customers or other contacts.

"Brand identity helps doctors see the patient behind the condition.” Vince Parry has spent his career at the forefront of the healthcare branding industry. He has launched some of the most iconic healthcare brands, such as Lipitor, Botox, and Prozac. He has also been instrumental in transforming the way society is educated about illness and the possible options for relief. We discussed all of this and more on this week’s episode of the On Brand podcast.   About Vince Parry Vince Parry, a 30-year veteran of the health and wellness communications industry is the founder of the Parry Branding Group. Throughout his distinguished career, Vince has worked on many of the most well-known corporate, franchise, service, and product brands. He was previously the Chief Branding Officer at inVentiv Health, the Founder and President of Y Brand, the Founder and President of GSW NY and the Chief Creative Officer at Sudler & Hennessy. Vince has appeared on NBC Nightly News with Brian Williams and BBC radio, has been featured in Medical Marketing and Media, PharmaVoice, Pharmaceutical Executive, and MedAdNews, and guest lectures at the Rutgers Pharmaceutical MBA program on healthcare branding. He’s also the author of Identity Crisis: Health Care Branding's Hidden Problems and Proven Strategies to Solve Them. Episode Highlights Why is healthcare branding so different? “The big difference between consumer branding and healthcare branding is that consumer branding is a celebration of self. The new iPhone reinforces your identity. With healthcare branding, it restores your identity. It restores what an illness has taken away. It’s a protection.” Healthcare branding and storytelling. “Illness is a great drama.” That’s because it comes with an antagonist. Something else that you’re fighting against. “Take overactive bladder vs. incontinence. Overactive bladder personifies the illness.” “You can’t walk into a store and buy Lipitor.” We talked extensively about the challenge pharmaceutical marketing presents as the end-user can’t buy the product. But they can ask the physician. Vince stressed that you still need to educate the doctors on the drugs and illnesses as they don’t like being uninformed. What can other businesses learn from healthcare branding and marketing? You have to learn about your customers and asking questions is the best way to do that. “But you can’t ask direct questions like ‘How do you feel about this?’” Consumers today are informed about market research and can inadvertently skew their responses. That’s why you need to approach them in an indirect manner. What brand has made Vince smile recently? “If it’s a real smile I’d say the New York Yankees — because they’re my team, my brand.” Then Vince pointed us to more of a “shaking my head” smile at pharmaceutical brand Movantik, for their creation of the concept of opioid-induced constipation. “You mean … constipation?!?!” joked Vince. To learn more, go to parrybranding.com. As We Wrap … Before we go, I want to flip the microphone around to our community …Recently, Seth Price gave us a shout on Twitter for our episode featuring his Road to Recognition co-author Barry Feldman. Thanks for listening! Did you hear something you liked on this episode or another? Do you have a question you’d like our guests to answer? Let me know on Twitter using the hashtag #OnBrandPodcast and you may just hear your thoughts here on the show. Subscribe to the podcast – You can subscribe to the show via iTunes, Stitcher, and RSS. Rate and review the show – If you like what you’re hearing, head over to iTunes and click that 5-star button to rate the show. And if you have a few extra seconds, write a couple of sentences and submit a review. This helps others find the podcast. OK. How do you rate and review a podcast? Need a quick tutorial on leaving a rating/review in iTunes? Check this out. Register now and SAVE for Social Brand Forum 2017 — September 14, 2017, at the Iowa Memorial Union featuring past On Brand guests Jason Falls, Marcus Sheridan, Melissa Agnes, and more. Learn more. Remember – On Brand is brought to you by my new book — Get Scrappy: Smarter Digital Marketing for Businesses Big and Small. Order now at Amazon and check out GetScrappyBook.com for special offers and extras. Until next week, I’ll see you on the Internet!

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: INC Research, inVentiv Health, GSK, EMA, QuintilesIMS, PRA, Assobiotec, EUSA Pharma.Persone: Micheal Bell (inVentiv Health), Alistar Macdonald (INC Research), Rino Rappuoli (GKS), Guido Rasi (EMA), Beatrice Lorenzin (Ministro della Salute), Manlio Florenzano (Italian Biosimilars Group), Mark Sorrentino (PRA), Riccardo Palmisano (Assobiotec), Bruno Daniele (Ospedale Rummo di Benevento). Nuove terapie: dinutuximab beta, nivolumab.Patologie: neuroblastoma, tumore al fegato.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: INC Research, inVentiv Health, GSK, EMA, QuintilesIMS, PRA, Assobiotec, EUSA Pharma.Persone: Micheal Bell (inVentiv Health), Alistar Macdonald (INC Research), Rino Rappuoli (GKS), Guido Rasi (EMA), Beatrice Lorenzin (Ministro della Salute), Manlio Florenzano (Italian Biosimilars Group), Mark Sorrentino (PRA), Riccardo Palmisano (Assobiotec), Bruno Daniele (Ospedale Rummo di Benevento). Nuove terapie: dinutuximab beta, nivolumab.Patologie: neuroblastoma, tumore al fegato.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple

Our guest on this segment is 30-year veteran of the health and wellness communications industry. VINCE PARRY is the founder of the Parry Branding Group, and the author of Identity Crisis. In it he shares keen insights into the success of everyday brands and describes the keys to establishing brand preferences for medications and wellness goods. Vince was previously the Chief Branding Officer at inVentiv Health, the Founder and President of Y Brand, the Founder and President of GSW NY and the Chief Creative Officer at Sudler & Hennessey. He's appeared on NBC Nightly News with Brian Williams and BBC radio, has been featured in Medical Marketing and Media, PharmaVoice, Pharmaceutical Executive, and MedAdNews, and guest lectures at the Rutgers Pharmaceutical MBA program on healthcare branding. In his latest book, Identity Crisis, Parry shares keen insights into the success of everyday brands and describes the keys to establishing brand preferences for medications and wellness goods. Parry weaves examples from his work with industry leaders such as Merck, Bayer Healthcare, and Maimonides Medical Center, and reveals how differentiating healthcare brands have shaped our choices. By incorporating how we identify with illness and wellness into his innovative branding strategies, he has redefined how we make purchasing decisions to improve our lives and find relief. VINCE PARRY Parry Branding Group http://parrybrandinggroup.com/ (646) 850-4537 Learn more about your ad choices. Visit megaphone.fm/adchoices

Our guest on this segment is 30-year veteran of the health and wellness communications industry. VINCE PARRY is the founder of the Parry Branding Group, and the author of Identity Crisis. In it he shares keen insights into the success of everyday brands and describes the keys to establishing brand preferences for medications and wellness goods. Vince was previously the Chief Branding Officer at inVentiv Health, the Founder and President of Y Brand, the Founder and President of GSW NY and the Chief Creative Officer at Sudler & Hennessey. He's appeared on NBC Nightly News with Brian Williams and BBC radio, has been featured in Medical Marketing and Media, PharmaVoice, Pharmaceutical Executive, and MedAdNews, and guest lectures at the Rutgers Pharmaceutical MBA program on healthcare branding. In his latest book, Identity Crisis, Parry shares keen insights into the success of everyday brands and describes the keys to establishing brand preferences for medications and wellness goods. Parry weaves examples from his work with industry leaders such as Merck, Bayer Healthcare, and Maimonides Medical Center, and reveals how differentiating healthcare brands have shaped our choices. By incorporating how we identify with illness and wellness into his innovative branding strategies, he has redefined how we make purchasing decisions to improve our lives and find relief. VINCE PARRY Parry Branding Group http://parrybrandinggroup.com/ (646) 850-4537 Learn more about your ad choices. Visit megaphone.fm/adchoices

The power of the payer in the biopharmaceutical industry has increased dramatically over the past several years, according to Keith Kelly, Managing Director and Head of the Pricing and Market Access Practice of inVentiv Health Consulting. Market access was once a dull topic. Today, price and if a drug will be covered is discussed on earnings calls and in the board room. What payers do can make or break the stock price of a company overnight. In this episode, Kelly and host Jeff Stewart discuss what factors have contributed to the payer's rise in influence; how payers are wielding this power; why drug price negotiation is similar to discount suit shopping; and the “prisoner's dilemma” of acquiring access for products entering the market at the same or similar time. The pair also explores the nirvana concept of “sustainable market access” – is it even possible? – and the value creation equation for a pharmaceutical company looking to achieve it for their products. Data from this episode originated from the following sources: Gross to net pricing from Credit Suisse; manufacturing cost analysis published in the Journal of Pharmaceutical Innovation and Nature Biotechnology; and Hepatitic C drug costs covered in Reuters. The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements, or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter. The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. inVentiv Health reserves the right to make alterations or deletions to the content at any time without notice to you. inVentiv Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content. The information, data, and other content contained in this podcast is not a reflection of, endorsed by or otherwise affiliated with, nor should it be attributed to, any of inVentiv Health's clients, customers or other contacts.

Introduced on March 6, 2017, if passed the American Health Care Act of 2017 (AHCA) is expected to have an enormous impact on Pharma. The Congressional Budget Office (CBO) on March 13 released its estimate of the budgetary effects of the AHCA, stating that under the new law, we could see 14 million more uninsured by 2018 than would have been under the current law – rising to 24 million more uninsured by 2026. Our host Jeff Stewart sat down with inVentiv Health Consulting Pricing & Market Access Director Nicolle Hamilton, PhD and Meg Alexander, Head of the Reputation and Risk Management Practice for inVentiv Health Communications, to discuss key components of the AHCA, their potential implications and what it means for pharmaceutical companies. *As documented in this podcast, the effects are both direct and perceptual. Financially, $592B in revenues will no longer be spent on healthcare over the next 10 years, according to the CBO. Of that, an estimated $59B would have been spent on pharma. Perceptually, there is the potential that the public and politicians will blame the pharmaceutical industry and high drug prices for erosion of healthcare coverage. The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements, or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter. The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. inVentiv Health reserves the right to make alterations or deletions to the content at any time without notice to you. inVentiv Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content. The information, data, and other content contained in this podcast is not a reflection of, endorsed by or otherwise affiliated with, nor should it be attributed to, any of inVentiv Health's clients, customers or other contacts.

The passage of the 21st Century Cures Act earlier this year catapulted the concept of “real-world evidence” into the spotlight, with many biopharmaceutical companies wondering whether this could be the panacea the industry has been looking for to attain product success. We reflected on this topic with David Thompson, PhD, Senior Vice President, Real-World Evidence Consulting at inVentiv Health, after he moderated a keynote panel at the Biotech Showcase event alongside the popular JP Morgan Healthcare Conference in San Francisco this January. Bottom line, according to Thompson, is that it's complicated – but the fact of the matter is that approval alone no longer gets you to the end zone; more likely, it will get you to the 50-yard line. Appropriate use of real-world evidence can provide some degree of advantage for products entering the marketplace. Listen in to learn more from this discussion on real-world evidence, including why it's so complicated, where the FDA fits in, what it means to payers and how it can impact commercial success. The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements, or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter. The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. inVentiv Health reserves the right to make alterations or deletions to the content at any time without notice to you. inVentiv Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content. The information, data, and other content contained in this podcast is not a reflection of, endorsed by or otherwise affiliated with, nor should it be attributed to, any of inVentiv Health's clients, customers or other contacts.

As pharmaceutical companies, spurred by the Orphan Drug Act, have delved deeper into the development of drugs to treat rare diseases, they have forged closer ties with patient advocates. While these relationships are driven by mutual interest, tensions sometimes arise because of divergent needs. We spoke to Heather Gartman, regional managing director of InVentiv Health, about the firms recent white paper “The New Partnership Paradigm.” Gartman discussed how patient advocates can more effectively influence pharmaceutical companies, some of the mistake pharmaceutical companies make, and how the growing sophistication of patient advocates is changing the balance of power in these relationships.

Disruptive changes to the healthcare landscape are creating new tensions in the traditional relationship between pharmaceutical companies and patient advocacy groups, according to the findings of a report from InVentiv Health. The report, based on interviews with nearly four dozen representatives of patient advocacy organizations, finds patient advocates expect greater transparency from their pharmaceutical partners, want to play an increased role in clinical trial design and execution, and see a role for themselves in education campaigns for patients and providers. We spoke to Heather Gartman, regional managing director of InVentiv Health, about the report, the changing dynamics between pharmaceutical companies and patient advocacy organizations, and whether the long-term health of the symbiotic relationship is in jeopardy.

BZTalks: Chris Beaver (inVentiv Health) on free vs total assays by Future Science Group

Tonight's podcast is about inVentiv Health (VTIV), a stock that I first reviewed in my blog Stock Picks Bob's Advice a year ago to the day! The stock moved higher today in an otherwise anemic market and I take another look at this company, reviewing recent earnings, valuation numbers, Morningstar report, and a point & figure chart.